Eli Lilly and Company (NYSE:LLY) Shares Acquired by High Falls Advisors Inc

High Falls Advisors Inc increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.1% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 526 shares of the company’s stock after purchasing an additional 35 shares during the period. High Falls Advisors Inc’s holdings in Eli Lilly and Company were worth $476,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company in the second quarter valued at approximately $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company in the 2nd quarter valued at $36,000. Morton Brown Family Wealth LLC boosted its stake in Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares during the last quarter. Core Wealth Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares in the last quarter. Finally, Unique Wealth Strategies LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter worth $45,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $877.79 on Monday. The firm has a 50-day simple moving average of $896.10 and a two-hundred day simple moving average of $844.12. The stock has a market cap of $834.26 billion, a PE ratio of 129.28, a P/E/G ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. As a group, analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $915.18, for a total value of $47,927,061.42. Following the completion of the transaction, the insider now owns 97,247,403 shares of the company’s stock, valued at $88,998,878,277.54. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have sold 364,810 shares of company stock worth $339,366,198 over the last three months. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LLY. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Berenberg Bank lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.